Le Lézard
Classified in: Health
Subject: PLW

USPTO Denies Challenges to BTL's Patents Related to Muscle Stimulation and Body Shaping Technology


MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ -- BTL Industries, the manufacturer of the industry-leading Emsculpt® and Emsculpt NEO® body-contouring products, announced today that the Patent Trial and Appeal Board of the US Patent and Trademark Office denied eight petitions requesting institution of inter partes review of patents related to BTL's breakthrough magnetic technology for muscle toning and body shaping. The petitioner withdrew its remaining related petitions due to their substantial identity with the petitions denied.

With this recent conclusion of these proceedings, BTL successfully defended nine different patents across 28 Board proceedings, filed by two different petitioners over the last two years.

"In its recent decisions, the Board refused to initiate reviews of BTL's patents covering the muscle-toning technology incorporated in our popular Emsculpt® and Emsculpt NEO® products," explained David Chmel, VP of Operations. "The Board determined that the petitioner failed to meet its burden to show the unpatentability of the challenged claims."

"BTL spent years developing and commercializing the technology behind Emsculpt® and Emsculpt NEO®, which revolutionized the body contouring industry," said Ron Borsheim, VP of Business Development. "We have successfully proven the strength of our intellectual property rights protecting that technology, and we will relentlessly fight those who infringe our IP, especially entities who fraudulently try to import any knockoffs into the country."

About Emsculpt® and Emsculpt NEO®:
BTL's Emsculpt® has been a clear innovation leader in the muscle category, revolutionizing the non-invasive body shaping market. Utilizing its proprietary high intensity focused electromagnetic energy (HIFEM®), the Emsculpt introduced an entirely new category of muscle toning and muscle strengthening to the aesthetic industry. The Emsculpt NEO® combined HIFEM® and radiofrequency technology to tone muscle and break down fat.  For more details, go to www.bodybybtl.com.

MEDIA CONTACT:
[email protected]

SOURCE BTL Aesthetics


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: